CONNECT WITH US
HealthTech

HealthTech

Experimental blood test can detect four signs of deadly diseases in an hour

Medical Xpress logo

Published on

Add as a preferred source on Google
Experimental blood test can detect four signs of deadly diseases in an hour

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A new diagnostic platform is able to screen for and identify four different diseases—colorectal cancer, glioblastoma, pancreatic cancer and Alzheimer's disease—with a small amount of blood in an hour. The patent-pending technology was developed by a team of researchers led by Hsueh-Chia Chang at the University of Notre Dame.

The diagnostic platform was tested in a blind setting using 87 plasma samples from blood draws from patients who were either healthy or had one of the four diseases. The platform was found to be 90% to 99% accurate for detecting the presence or absence of each disease type.

"We believe that if we can screen these diseases earlier, then patients may have a better chance at surviving," said Chang, the Bayer Corporation professor of engineering in the Department of Chemical and Biomolecular Engineering at Notre Dame. The study is published in Nature Biomedical Engineering.

The disease detection platform works by detecting exosomes found in the blood, which carry proteins that can provide an early indication of disease. To detect these proteins, the Chang Lab created immunojanus particles, or tiny spheres that have two distinct halves. One half is affixed with antibodies and the other is fluorescent.

To run a test, 10 microliters of blood is diluted with a saline solution and mixed with immunojanus particles for 10 to 60 minutes, allowing the immunojanus particles to fully disperse throughout the blood mixture.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.